Program
Triamcinolone Acetonide
Also written as “triamcinolone acetonide”, “SC CLS-TA” and “suprachoroidal CLS-TA”.
Its studies are mostly in Macular Edema · Uveitis · Diabetes Mellitus · Keloid · Pain, led by 12 companies.
Drug pageTriamcinolone Acetonide: every studyMany companies study it; this page follows only the 20 they lead. All 194 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Clearside Biomedicalits history only | 70 open or running | phase 3since Oct 28, 2015 | Feb 5, 2013 | none ahead |
| Pacira BioSciencesits history only | 21 open or running | phase 3since Feb 13, 2024 | Feb 13, 2024 | Dec 2026phase 3 · NCT06269705 |
| Sanofiits history only | 20 open or running | phase 3since Jun 26, 2006 | Jun 26, 2006 | none ahead |
| Alconits history only | 10 open or running | phase 3since Sep 19, 2007 | Sep 19, 2007 | none ahead |
| Biosplice Therapeuticsits history only | 10 open or running | phase 1since Oct 6, 2020 | Oct 6, 2020 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since Oct 31, 2013 | Oct 31, 2013 | none ahead |
| Harrowits history only | 11 open or running | phase 3since Sep 14, 2026 | Sep 14, 2026 | Dec 2026phase 3 · NCT07832552 |
| Merckits history only | 10 open or running | phase 2since Jun 4, 2008 | Jun 4, 2008 | none ahead |
| Novartisits history only | 10 open or running | phase 3since Oct 19, 2005 | Oct 19, 2005 | none ahead |
| Oxularits history only | 10 open or running | phase 2since Aug 20, 2022 | Aug 20, 2022 | none ahead |
| PT. Prodia Stem Cell Indonesiaits history only | 10 open or running | phase 2since Mar 26, 2020 | Mar 26, 2020 | none ahead |
| SurModicsits history only | 10 open or running | phase 1since Jun 4, 2009 | Jun 4, 2009 | none ahead |
Also a collaborator on its studies: QLT.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 6 studies since Oct 19, 2005.
- Oct 31, 2013GlaxoSmithKline’s first study: phase 1 study in FibrosisNew to GlaxoSmithKlineGlaxoSmithKline · NCT01978301 · 9 enrolled · United Kingdom
- Oct 28, 2015Phase 3 study in UveitisClearside Biomedical · NCT02595398 · 160 enrolled · United States, India, Israel
- Oct 25, 2016Phase 2 study in Diabetes MellitusClearside Biomedical · NCT02949024 · 20 enrolled · United States
- Nov 30, 2016Phase 3 study in Macular EdemaClearside Biomedical · NCT02980874 · 460 enrolled · United States, Australia, Austria and more
- Mar 27, 2017Phase 3 study in UveitisClearside Biomedical · NCT03097315 · 38 enrolled · United States
- Apr 20, 2017Phase 2 study in Diabetes MellitusClearside Biomedical · NCT03126786 · 71 enrolled · United States
- Jun 28, 2017Phase 3 study in Macular EdemaClearside Biomedical · NCT03203447 · 325 enrolled · United States, Australia, Hungary and more
- Oct 18, 2017Phase 3 study in Rhinitis, Allergic, PerennialSanofi · NCT03317015 · 260 enrolled
- Mar 26, 2020PT. Prodia Stem Cell Indonesia’s first study: phase 2 study in KeloidNew to PT. Prodia Stem Cell IndonesiaPT. Prodia Stem Cell Indonesia · NCT04326959 · 24 enrolled
- Oct 6, 2020Biosplice Therapeutics’ first study: phase 1 study in Drug-Drug InteractionNew to Biosplice TherapeuticsBiosplice Therapeutics · NCT04598542 · 40 enrolled · United States
- Aug 20, 2022Oxular’s first study: phase 2 study in Diabetic Macular EdemaNew to OxularOxular · NCT05512962 · 25 enrolled · United States
- Feb 13, 2024Pacira BioSciences’ first study: phase 3 study in Glenohumeral OsteoarthritisNew to Pacira BioSciencesPacira BioSciences · NCT06269705 · 150 enrolled · United States
- May 7, 2025Phase 2 study in Osteoarthritis, HipPacira BioSciences · NCT06977568 · 1 enrolled · United States
- Sep 14, 2026Harrow’s first study: phase 3 study in Postoperative Ocular InflammationNew to HarrowHarrow · NCT07832552 · 250 planned · United States
Ahead
- Dec 2026Primary completion: phase 3 study in Postoperative Ocular InflammationHarrow · NCT07832552
- Dec 2026Primary completion: phase 3 study in Glenohumeral OsteoarthritisPacira BioSciences · NCT06269705
TargetBeta
“Glucocorticoid receptor agonist”ChEMBL 37, by rule
Other programs on NR3C1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Dexamethasonerule | AbbVie | phase 4 | 174 |
| Budesoniderule | AstraZeneca | phase 4 | 167 |
| fluticasone furoaterule | GlaxoSmithKline | phase 4 | 97 |
| Prednisonerule | Johnson & Johnson | phase 4 | 65 |
| Beclomethasonerule | Chiesi Farmaceutici | phase 4 | 46 |
| Prednisolonerule | Sanofi | phase 4 | 34 |
| betamethasone dipropionaterule | LEO Pharma | phase 4 | 27 |
| Methylprednisolonerule | Pfizer | phase 4 | 23 |
| dexamethasone phosphaterule | eyegate-pharmaceuticals-inc | phase 4 | 21 |
| Betamethasonerule | LEO Pharma | phase 4 | 9 |
| Triamcinolonerule | research-insight-llc | phase 4 | 5 |
| relacorilantrule | Corcept Therapeutics | phase 3 | 22 |
Studies
All 20 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07832552Postoperative Ocular Inflammation · United States | 3 | By invitation | Harrow | Dec 2026 | 250 |
| NCT06977568Osteoarthritis, Hip · United States | 2 | Terminated | Pacira BioSciences | Oct 16, 2025 | 1 |
| NCT06269705Glenohumeral Osteoarthritis · United States | 3 | Active, not recruiting | Pacira BioSciences | Dec 2026 | 150 |
| NCT05512962Diabetic Macular Edema · United States | 2 | Completed | Oxular | Nov 30, 2023 | 25 |
| NCT04598542Drug-Drug Interaction · United States | 1 | Completed | Biosplice Therapeutics | Dec 22, 2020 | 40 |
| NCT04326959Keloid | 2 | UNKNOWN | PT. Prodia Stem Cell Indonesia | Sep 8, 2020 | 24 |
| NCT03317015Rhinitis, Allergic, Perennial | 3 | Completed | Sanofi | Jul 10, 2017 | 260 |
| NCT03203447Macular Edema · United States, Australia, Hungary and more | 3 | Terminated | Clearside Biomedical | Dec 18, 2018 | 325 |
| NCT03126786Diabetes Mellitus · United States | 2 | Completed | Clearside Biomedical | Apr 17, 2018 | 71 |
| NCT03097315Uveitis · United States | 3 | Completed | Clearside Biomedical | Jan 24, 2018 | 38 |
| NCT02980874Macular Edema · United States, Australia, Austria and more | 3 | Terminated | Clearside Biomedical | Dec 10, 2018 | 460 |
| NCT02949024Diabetes Mellitus · United States | 2 | Completed | Clearside Biomedical | Oct 17, 2017 | 20 |
| NCT02595398Uveitis · United States, India, Israel | 3 | Completed | Clearside Biomedical | Jan 18, 2018 | 160 |
| NCT01978301Fibrosis · United Kingdom | 1 | Terminated | GlaxoSmithKline | Feb 5, 2015 | 9 |
| NCT01789320Uveitis · United States | 2 | Completed | Clearside Biomedical | Mar 2015 | 11 |
| NCT00915837Diabetic Macular Edema · United States | 1 | Completed | SurModics | Apr 2009 | 31 |
| NCT00692614Macular Edema | 2 | Terminated | Merck | Nov 2008 | 2 |
| NCT00532415Vitrectomy | 3 | Completed | Alcon | Sep 2007 | 60 |
| NCT00344942Rhinitis · France | 3 | Terminated | Sanofi | Apr 2007 | 77 |
| NCT00242580Macular Degeneration · United States | 3 | Completed | Novartis | Jan 2008 | 111 |
How it is read
Names in the registry
- “triamcinolone acetonide”, 4 entries
- “Triamcinolone Acetonide”, 2 entries
- “SC CLS-TA”, 2 entries
- “suprachoroidal CLS-TA”, 2 entries
- “Triamcinolone acetonide”, 2 entries
Conditions, from the studies’ own filings
- Macular Edema, 5 studies
- Uveitis, 3 studies
- Diabetes Mellitus, 2 studies
- Keloid, 2 studies
- Pain, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.